Pharmalot Ed Silverman STAT Plus: Little transparency, lots of waste: NIH funds pediatric research, but many trials results go unpublished
Pharmalot Ed Silverman STAT Plus: Charles River suspends shipments of monkeys used in research amid federal probe
Pharmalot Ed Silverman STAT Plus: Government watchdog calls for stronger oversight of for-profit research review boards
Biotech Allison DeAngelis STAT Plus: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues
Health Tech Casey Ross STAT Plus: Verily, struggling to turn profits, taps a Starbucks veteran and ‘Warcraft’ master
Exclusive Matthew Herper and Casey Ross STAT Plus: Verily leans into Onduo as it looks to enter the lucrative world of running medical research
Health Olivia Goldhill ‘Intriguing and sobering’: Enthusiasm over psilocybin’s effect on depression tempered by questions about durability
Biotech Allison DeAngelis STAT Plus: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Biotech Alex Hogan and Damian Garde STAT Plus: Watch: P-value, an important measurement in clinical trials, explained
Opinions+ Irfan Khan STAT Plus: Developing new drugs starts with building the next generation of clinical investigators
Pharmalot Ed Silverman STAT Plus: FDA is petitioned to boost enforcement of trial sponsors that fail to register studies or report results
Pharmalot Ed Silverman STAT Plus: Many pediatric drug study results were never posted to a U.S. government database
Pharmalot Ed Silverman and John Wilkerson STAT Plus: Pallone pushes NIH and FDA to disclose steps being taken to ensure clinical trial results are reported
Biotech Jason Mast STAT Plus: As FDA considers new Alzheimer’s drug, a case study details safety concerns
Pharmalot Ed Silverman STAT Plus: Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’
Biotech Angus Chen STAT Plus: Novartis develops CAR-T therapy that can be made in a fraction of the standard time
Health Ambar Castillo STAT Plus: ‘All the tech in the world doesn’t solve this’: Rare disease experts push biopharma on equity
In the Lab Angus Chen STAT Plus: In ‘landmark’ study, cell therapy exceeds expectations in melanoma patients
Health Kay Lazar — Boston Globe STAT Plus: The secret to longer, healthier life? Ambitious new trial focuses on ‘super agers’ and seeks thousands of families.
Health Usha Lee McFarling En la frontera entre Texas y México, nace un audaz plan para diversificar la investigación sobre el Alzheimer
Pharmalot Ed Silverman STAT Plus: After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results
A STAT Investigation Jason Mast STAT Plus: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups
Health Angus Chen ‘It still prevented cancers’: Experts discuss furor over colonoscopy screening study and dissect the nuances
Health Tech Katie Palmer STAT Plus: At Verily, a growing line of business builds on a revolving door to the FDA
Health Tech Mario Aguilar STAT Plus: Health app companies wrestle with how to design studies to prove treatments work
Health Usha Lee McFarling On the Texas-Mexico border, a bold plan to diversify Alzheimer’s research takes shape
Pharmalot Ed Silverman STAT Plus: Some European regulators are starting to take steps to ensure clinical trial results are reported
Politics Ambar Castillo STAT Plus: House Democrat presses bill to encourage more diversity in clinical trials run by NIH
Biotech Jason Mast STAT Plus: Cancer treatment devised in the 1980s has proven effective (again). Will it finally get approval?